Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
Monica M. Bertagnolli(National Institutes of Health), Asad Umar(Center for Cancer Research), Bruce Salzberg(Atlanta Gastroenterology Associates), Ernest T. Hawk(The University of Texas MD Anderson Cancer Center), John Burn(Newcastle University), Donya Bagheri(CCS Associates (United States)), T. Raymond Foley(Lancaster General Hospital), Ann G. Zauber(Memorial Sloan Kettering Cancer Center), Aurora Breazna(Houston Methodist), Finlay Macrae(The Royal Melbourne Hospital), Rebecca B. Rosenstein(Pfizer (United States)), Thomas Sylwestrowicz(University of Saskatchewan), Thomas Dewar(Texas Health Harris Methodist Hospital Fort Worth), Neal T. Collins(Houston Methodist), John R. Saltzman(Brigham and Women's Hospital), Jie Tang(Bengbu Medical College), Daniel C. Chung(Massachusetts General Hospital), Mark Redston(Brigham and Women's Hospital), Craig Eagle(Pfizer (United States)), Ronald E. Pruitt(Nashville Medical Research Institute), KyungMann Kim(Houston Methodist), Neville E. Hoffman(Sir Charles Gairdner Hospital)
Cited by 193
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k